Genmab A/S: shareholders and insiders

GMABNASDAQHealthcare · Pharmaceutical Preparations

Price

$50.60

November 20, 2026Market cap $32.5B

What Ploutos Investor adds for Genmab A/S

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors, from their own Form 4 filings.

Sorry, we do not have enough data

for purchases and sales by Genmab A/S's insiders

Why?

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%Oct 5, 2026 Latest filing
  • Darwin Global Management, Ltd.with 2 more persons
    Share of class5.90%
  • BlackRock, Inc.
    Share of class5.60%
  • Orbis Investment Managementwith 1 more person
    Share of class5.30%

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter×26.1
  • Renaissance Technologies
    In the quarter-35%
  • Citadel Advisors (Griffin)
    In the quarter-30%
  • Millennium Mgmt (Englander)
    In the quarter-17%
  • AQR Capital
    In the quarter+26%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short sales in daily trading

How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.

40.6% the last 14 sessions-13.6 pts vs the 14 before

In the last 14 sessions, 40.6% of the shares in the reported trades were short sales, against 54.2% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
40.6%
The 14 beforeOct 14, 2026 – Nov 2, 2026
54.2%
Change
-13.6 pts
Short sales a dayon average, of 1.66M shares
675.4K
More than atof 3,666 US-listed companies, same days
21%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 66.6%
  • Oct 15, 2026: Short sales 64.4%
  • Oct 16, 2026: Short sales 43.6%
  • Oct 19, 2026: Short sales 47.2%
  • Oct 20, 2026: Short sales 71.4%
  • Oct 21, 2026: Short sales 44.2%
  • Oct 22, 2026: Short sales 66.2%
  • Oct 23, 2026: Short sales 59.5%
  • Oct 26, 2026: Short sales 64.5%
  • Oct 27, 2026: Short sales 58.2%
  • Oct 28, 2026: Short sales 61%
  • Oct 29, 2026: Short sales 31.4%
  • Oct 30, 2026: Short sales 28.9%
  • Nov 2, 2026: Short sales 44.9%
  • Nov 3, 2026: Short sales 38.1%
  • Nov 4, 2026: Short sales 42%
  • Nov 5, 2026: Short sales 33.9%
  • Nov 6, 2026: Short sales 17.6%
  • Nov 9, 2026: Short sales 48.7%
  • Nov 10, 2026: Short sales 50.6%
  • Nov 11, 2026: Short sales 55.5%
  • Nov 12, 2026: Short sales 56.3%
  • Nov 13, 2026: Short sales 47.7%
  • Nov 16, 2026: Short sales 46.3%
  • Nov 17, 2026: Short sales 65.9%
  • Nov 18, 2026: Short sales 41.5%
  • Nov 19, 2026: Short sales 41%
  • Nov 20, 2026: Short sales 31.4%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

28 ETFs holding it1.12% The largest weight (IBB)
  • IBBiShares Biotechnology ETF
    Weight in the fund1.12%
  • IXJiShares Global Healthcare ETF
    Weight in the fund0.22%
  • DFIVDimensional International Value ETF
    Weight in the fund0.17%
  • EFGiShares MSCI EAFE Growth ETF
    Weight in the fund0.16%
  • IEURiShares Core MSCI Europe ETF
    Weight in the fund0.11%
  • VGKVanguard European Stock Index Fund
    Weight in the fund0.11%
  • AVDEAvantis International Equity ETF
    Weight in the fund0.10%
  • DBEFXtrackers MSCI EAFE Hedged Equity ETF
    Weight in the fund0.09%
  • EFAViShares MSCI EAFE Min Vol Factor ETF
    Weight in the fund0.08%
  • EFAiShares MSCI EAFE ETF
    Weight in the fund0.08%

28 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

290 Managers, Q2 2026$2.8B Value of their positions
  • Q3 2025: Managers 253
  • Q4 2025: Managers 294
  • Q1 2026: Managers 276
  • Q2 2026: Managers 290

Institutional investors by quarter

The fund managers holding GMAB, quarter by quarter, from Q1 2014 to Q2 2025, 40 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 290 managers held 102M shares, worth $2.8B. During the quarter 50 opened a position, 36 closed one, 101 added and 98 trimmed.

The largest holders, Q2 2026

  • Paradigm Biocapital Advisors
    In the quarter+65%
  • Orbis Allan Gray
    In the quarter-12%
  • Alliancebernstein
    In the quarter-9.5%
  • Deerfield Management
    In the quarter+179%
  • Deep Track Capital
    In the quarter+54%
  • Arrowstreet Capital, Limited Partnership
    In the quarter
  • BlackRock
    In the quarter+3.0%
  • Sofinnova Investments
    In the quarter+438%
  • Renaissance Technologies
    In the quarter-20%
  • Two Sigma Investments
    In the quarter+50%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Genmab A/S's filings show?

Who buys and sells is one part of Genmab A/S's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about GMAB's shareholders

Didn't find what you were looking for?

Ask us
Have GMAB's insiders bought or sold?

From – to – Genmab A/S's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold GMAB?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $126M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.